Loading…
← CockpitCompetitor Analysis › SGRY Surgery Partners, Inc.Open in the cockpit ↗

Surgery Partners, Inc.SGRYCompetitor analysis, valuation and peers

United States · USD·Health Care›Hospital/Nursing Management

Owns and operates ambulatory surgery centers and surgical hospitals performing outpatient procedures across specialties.

Momentum leader 99
Mkt cap
$3.53B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$182M
20-day average traded
Fwd P/E
77.2×
forward earnings
ROIC−WACC
-4.9 pp
WACC 10.1%
Hurdle
+3 pp
Req g minus delivered
Next earnings
103 days
1 Mar 2027
Close · USD$26.96
1D+0.4%
1W+1.1%
1M+74.0%
3M+93.4%
6M+99.8%
YTD+74.5%
1Y+79.0%
ATR %2.4%
Beta1.06
52w lowhigh1.0% off high

What Surgery Partners does

Owns and operates ambulatory surgery centers and surgical hospitals performing outpatient procedures across specialties.

Is paid facility fees by insurers and Medicare for each procedure, while surgeons bill separately, and its centers are jointly owned with local physicians who hold minority stakes. Case volumes and insurer rate negotiations drive results. Private-equity firm Bain Capital is its largest shareholder.

Products and services

  • Ambulatory surgery centers
  • Surgical hospitals
  • Ancillary services (anesthesia, imaging)

Customers

  • Physician partners
  • Health insurers
  • Patients

Where it sits in the supply chain

  • Healthcare services
  • Outpatient surgical facilities
  • Ambulatory surgery center operator

What could go right

  • Site-of-care shift from hospitals to ASCs
  • Physician partnership growth

What could go wrong

  • Payer reimbursement pressure
  • High leverage

Moat: narrow (scale, regulatory licence). Physician-partnership model and facility licensing create switching costs versus building new centers.

Headquarters: Brentwood, Tennessee, United States · Founded: 2004 · Employees: 16,000

Named competitors

Surgery Partners at a glance

Size Surgery Partners (SGRY) is a United States Health Care company (Hospital/Nursing Management) with a market value of $3.53B, the 1422nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.96 on 18 Nov 2026.

Performance Over six months the shares gained 99.8%, against -0.9% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 2.2% over the last twelve months (peer median +12.9%); the operating margin is 12.8% (peer median 9.4%).

Valuation It trades at 77.2× forward earnings against a peer median of 37.3× (5th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.9 points below its cost of capital (10.1% WACC).

Short interest Short interest is 7.0% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026SGRY 203Peer median 99
Six months, rebased to 100: Surgery Partners against the median of its 20 peers (local-currency closes).

Surgery Partners financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$3.36B$3.31B$3.11B$2.74B$2.54B
Revenue growth—+6%+14%+8%—
Gross profit$570M$589M$593M$529M$460M
EBITDA$608M$647M$608M$527M$508M
Net income-$87.0M-$77.9M-$168M-$11.9M-$54.6M
Free cash flow$203M$196M$210M$205M$78.2M
Capital expenditure$75.1M$78.7M$90.4M$88.8M$80.6M
Total debt$3.31B$4.02B$3.70B$3.06B$2.93B

Quarterly statements and history in the cockpit →

Surgery Partners competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+25%+50%KIMSNHCMEDANTANH600763BKDARDTFORTIS301267CHEPACSSIARHCAEVS301293SPISGRY6-month return →1-month return →
Up and to the right = strong over both horizons. Surgery Partners is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×KIMSMEDANTANH600763BKDARDTFORTISEXEASTERDMPACSSIAAEVS301293SGRYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Surgery Partners is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%NHCNH600763BKDARDTFORTISASTERDM301267CHEPACSSIARHC000516AEVSRAINBOWSGRYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Surgery Partners is the large dot.

Surgery Partners competitors and peer comparison

Head to head with its named competitors (SGRY vs THC vs HCA vs UHS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Surgery Partners SGRY$3.53B+100%+2%13%77.2×15.6%
Tenet Healthcare THC$21.6B+45%+6%17%13.4×-1.4%
HCA Healthcare HCA$99.5B+20%+6%15%15.6×3.1%
Universal Health Services UHS$10.7B+13%+8%11%8.3×-1.8%
Community Health Systems CYHn/a-34%n/an/an/an/a

How Surgery Partners compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Surgery Partners against its 20 peers (data as of 18 Nov 2026)
MeasureSGRYPeer medianRank in peer set
1-month return+74.0%+1.7%highest of 21
6-month return+99.8%-0.9%highest of 21
Distance from 52-week high-1.0%-18.4%2nd highest of 21
Revenue growth (TTM)+2.2%+12.9%5th lowest of 21
Operating margin12.8%9.4%8th highest of 21
Forward P/E77.2×37.3×5th most expensive of 19
Growth the price implies (Req g, 7 yrs)15.6%12.7%8th most demanding of 18
Growth delivered (Del g)+12.2%+9.7%6th highest of 18
Hurdle (Req g minus delivered)+3.4 pp+5.5 pp9th least demanding of 18
ROIC minus cost of capital-4.9 pp-2.5 pp6th lowest of 21
EV / EBITDA13.3×19.8×4th cheapest of 15
Net debt / EBITDA4.9×3.3×7th most indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Surgery Partners SGRYUnited States$3.53B+100%+2%13%77.2×15.6%+12.2%
Krishna Institute of Medical Sciences KIMS.NSIndia$3.41B+2%+35%11%81.9×n/an/a
National HealthCare NHCUnited States$3.16B+1%+6%0%n/a6.4%+9.7%
Global Health MEDANTA.NSIndia$4.13B+16%+26%17%50.4×n/an/a
Narayana Hrudayalaya NH.NSIndia$4.13B0%+71%13%34.2×31.2%+25.0%
Topchoice Medical 600763.SSChina$2.33B-12%+7%26%24.8×12.4%+6.9%
Brookdale Senior Living BKDUnited States$2.06B-36%-8%6%482.6×19.3%-1.4%
Ardent Health ARDTUnited States$2.03B+52%+2%5%11.9×-1.7%+8.7%
Fortis Healthcare FORTIS.NSIndia$6.40B-17%+18%17%48.5×42.5%+17.9%
Extendicare EXE.TOCanada$1.91B-16%+36%9%19.3×10.8%+8.5%
Aster DM Quality Care ASTERDM.NSIndia$6.83B-2%+50%16%63.5×48.6%-11.6%
Huaxia Eye Hospital 301267.SZChina$1.78B-18%+2%15%23.5×2.1%+10.4%
Chemed CHEUnited States$7.12B+24%+5%14%20.2×3.3%+4.0%
PACS PACSUnited States$7.35B+25%+11%8%17.5×7.5%+29.7%
Sienna Senior Living SIA.TOCanada$1.58B-8%+15%10%40.9×18.9%+8.6%
Ramsay Health Care RHC.AXAustralia$8.31B+41%+4%5%31.4×14.0%+8.3%
Xi'an International Medical Investment 000516.SZChina$1.46B-2%-1%-2%n/a12.7%+20.6%
Aevis Victoria AEVS.SWSwitzerland$1.43B+8%+15%-6%106.8×26.5%+10.2%
Rainbow Childrens Medicare RAINBOW.NSIndia$1.37B-7%+23%22%40.4×30.7%+21.2%
Sanbo Hospital Management 301293.SZChina$1.35B-29%+17%6%135.5×n/an/a
Spire Healthcare SPI.LUnited Kingdom$1.31B+11%+2%8%25.1×10.0%+11.4%

Questions

Who are Surgery Partners's main competitors?
Named competitors: Tenet Healthcare (USPI) (THC), HCA Healthcare (HCA), SCA Health (private or unlisted), Envision Healthcare (private or unlisted), Universal Health Services (UHS), Community Health Systems (CYH). The cockpit's measured peer set (industry) also includes Krishna Institute of Medical Sciences (KIMS.NS), National HealthCare (NHC), Global Health (MEDANTA.NS), Narayana Hrudayalaya (NH.NS), Topchoice Medical (600763.SS), Brookdale Senior Living (BKD).
Is Surgery Partners expensive compared with its peers?
On forward p/e it trades at 77.2× against a peer median of 37.3×, 5th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Surgery Partners stock performed?
Over six months to 18 Nov 2026 the shares returned +99.8% against -0.9% for the median peer; over one year +79.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.